This page uses content from Wikipedia and is licensed under CC BY-SA.


Evenamide structure.png
Clinical data
SynonymsNW-3509; NW-3509A
ATC code
  • None
CAS Number
PubChem CID
Chemical and physical data
Molar mass278.390 g/mol g·mol−1
3D model (JSmol)

Evenamide (INN) (developmental code names NW-3509, NW-3509A) is a selective voltage-gated sodium channel blocker, including (and not limited to) subtypes Nav1.3, Nav1.7, and Nav1.8, which is described as an antipsychotic and is under development by Newron Pharmaceuticals as an add-on therapy for the treatment of schizophrenia.[1][2][3][4] The drug has shown efficacy in animal models of psychosis, mania, depression, and aggression.[3] It has completed phase I clinical trials, and phase II clinical trials will be commenced in the third quarter of 2015.[5]

See also


  1. ^ "Drug Development in Schizophrenia: Summary and Table". Pharmaceutical Medicine. 28 (5): 265–271. 2014. doi:10.1007/s40290-014-0070-6. ISSN 1178-2595.
  2. ^ Progress in Medicinal Chemistry. Elsevier. 6 October 2010. pp. 81–. ISBN 978-0-12-381293-3.
  3. ^ a b Satya Prakash Gupta (21 June 2011). Ion Channels and Their Inhibitors. Springer Science & Business Media. pp. 102–. ISBN 978-3-642-19922-6.
  4. ^ Zuliani, Valentina; Amori, Laura; Rivara, Mirko (2011). "Advances in Design and Development of Sodium Channel Blockers": 79–115. doi:10.1007/978-3-642-19922-6_4. Cite journal requires |journal= (help)
  5. ^ []

External links